Which has better valuation & earnings, VOR or DNTH?

Vor Biopharma has higher earnings, but lower revenue than Dianthus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Dianthus Therapeutics $2.04M 2,084.01 -$162.34M -$4.15 N/A

Does the media refer more to VOR or DNTH?

In the previous week, Dianthus Therapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Dianthus Therapeutics' score of 0.64 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, EWTX or VOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is EWTX or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Vor Biopharma N/A N/A N/A

Does the media prefer EWTX or VOR?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Edgewise Therapeutics' score of 0.20 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, VOR or TNGX?

Vor Biopharma has higher earnings, but lower revenue than Tango Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Tango Therapeutics $62.38M 60.06 -$101.59M -$0.85 N/A

Is VOR or TNGX more profitable?

Vor Biopharma's return on equity of 0.00% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Tango Therapeutics N/A -25.75% -23.36%

Does the media favor VOR or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Tango Therapeutics and 2 mentions for Vor Biopharma. Tango Therapeutics' average media sentiment score of 1.29 beat Vor Biopharma's score of 0.91 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, VOR or RLAY?

Vor Biopharma has higher earnings, but lower revenue than Relay Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Relay Therapeutics $15.35M 247.84 -$276.48M -$1.57 N/A

Is VOR or RLAY more profitable?

Vor Biopharma's return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Relay Therapeutics N/A -42.27% -38.67%

Does the media refer more to VOR or RLAY?

In the previous week, Relay Therapeutics had 9 more articles in the media than Vor Biopharma. MarketBeat recorded 11 mentions for Relay Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Relay Therapeutics' score of 0.66 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, VOR or ABCL?

Vor Biopharma has higher earnings, but lower revenue than AbCellera Biologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A AbCellera Biologics $75.13M 51.46 -$146.41M -$0.54 N/A

Does the media favor VOR or ABCL?

In the previous week, AbCellera Biologics had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for AbCellera Biologics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat AbCellera Biologics' score of 0.38 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vor Biopharma (VOR) Competitors

$19.02 -0.04 (-0.20%)

As of 12:27 PM Eastern

Compare

VOR vs. DNTH, EWTX, TNGX, RLAY, and ABCL

Should you buy Vor Biopharma stock or one of its competitors? Vor Biopharma's main competitors and comparable companies include Dianthus Therapeutics (DNTH), Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), Relay Therapeutics (RLAY), and AbCellera Biologics (ABCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vor Biopharma compare to Dianthus Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Dianthus Therapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Dianthus Therapeutics' score of 0.64 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Vor Biopharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Vor Biopharma has higher earnings, but lower revenue than Dianthus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Dianthus Therapeutics	$2.04M	2,084.01	-$162.34M	-$4.15	N/A

Vor Biopharma presently has a consensus target price of $41.71, suggesting a potential upside of 118.86%. Dianthus Therapeutics has a consensus target price of $129.83, suggesting a potential upside of 67.35%. Given Vor Biopharma's higher probable upside, equities analysts plainly believe Vor Biopharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Vor Biopharma has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vor Biopharma beats Dianthus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Vor Biopharma (NASDAQ:VOR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Edgewise Therapeutics presently has a consensus target price of $51.33, suggesting a potential upside of 41.49%. Vor Biopharma has a consensus target price of $41.71, suggesting a potential upside of 118.86%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Edgewise Therapeutics' score of 0.20 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Vor Biopharma	N/A	N/A	N/A

97.3% of Vor Biopharma shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Edgewise Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

Summary

Vor Biopharma beats Edgewise Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Vor Biopharma compare to Tango Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Vor Biopharma has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Vor Biopharma currently has a consensus price target of $41.71, indicating a potential upside of 118.86%. Tango Therapeutics has a consensus price target of $43.46, indicating a potential upside of 95.60%. Given Vor Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vor Biopharma is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Tango Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Tango Therapeutics and 2 mentions for Vor Biopharma. Tango Therapeutics' average media sentiment score of 1.29 beat Vor Biopharma's score of 0.91 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma has higher earnings, but lower revenue than Tango Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Tango Therapeutics	$62.38M	60.06	-$101.59M	-$0.85	N/A

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vor Biopharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Tango Therapeutics	N/A	-25.75%	-23.36%

Summary

Vor Biopharma beats Tango Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Vor Biopharma compare to Relay Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Relay Therapeutics had 9 more articles in the media than Vor Biopharma. MarketBeat recorded 11 mentions for Relay Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Relay Therapeutics' score of 0.66 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market.

Vor Biopharma currently has a consensus target price of $41.71, indicating a potential upside of 118.86%. Relay Therapeutics has a consensus target price of $25.92, indicating a potential upside of 49.29%. Given Vor Biopharma's higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Vor Biopharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Relay Therapeutics	N/A	-42.27%	-38.67%

Vor Biopharma has higher earnings, but lower revenue than Relay Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Relay Therapeutics	$15.35M	247.84	-$276.48M	-$1.57	N/A

Summary

Vor Biopharma beats Relay Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Vor Biopharma compare to AbCellera Biologics?

Vor Biopharma (NASDAQ:VOR) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Vor Biopharma has higher earnings, but lower revenue than AbCellera Biologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
AbCellera Biologics	$75.13M	51.46	-$146.41M	-$0.54	N/A

Vor Biopharma currently has a consensus price target of $41.71, suggesting a potential upside of 118.86%. AbCellera Biologics has a consensus price target of $13.89, suggesting a potential upside of 10.14%. Given Vor Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vor Biopharma is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

In the previous week, AbCellera Biologics had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for AbCellera Biologics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat AbCellera Biologics' score of 0.38 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Vor Biopharma has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. Vor Biopharma's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
AbCellera Biologics	-248.83%	-17.49%	-12.36%

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Vor Biopharma beats AbCellera Biologics on 9 of the 13 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.12B	$3.89B	$7.28B	$13.01B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	N/A	12.99	275.44	25.42
Price / Sales	N/A	1,141.69	559.80	78.81
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	N/A	16.88	10.66	5.96
Net Income	N/A	-$22.65M	$3.50B	$380.62M
7 Day Performance	1.28%	-5.64%	-3.65%	-3.75%
1 Month Performance	-17.59%	-13.53%	-8.06%	-6.62%
1 Year Performance	-38.26%	6.87%	2.58%	-4.38%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	2.4668 of 5 stars	$19.02 -0.2%	$41.71 +119.3%	-41.0%	$1.12B	N/A	N/A	76
DNTH Dianthus Therapeutics	2.4678 of 5 stars	$82.37 -0.1%	$129.83 +57.6%	+125.4%	$4.51B	$2.04M	N/A	92	News Coverage
EWTX Edgewise Therapeutics	2.7215 of 5 stars	$39.06 -0.4%	$51.33 +31.4%	+146.6%	$4.24B	N/A	N/A	127	Analyst Forecast
TNGX Tango Therapeutics	2.1418 of 5 stars	$23.81 +5.5%	$43.46 +82.5%	+162.3%	$4.01B	$62.38M	N/A	137	Positive News
RLAY Relay Therapeutics	2.4258 of 5 stars	$17.88 +2.7%	$25.92 +44.9%	+176.9%	$3.92B	$15.35M	N/A	192

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. DNTH, EWTX, TNGX, RLAY, and ABCL

How does Vor Biopharma compare to Dianthus Therapeutics?

Summary

How does Vor Biopharma compare to Edgewise Therapeutics?

Summary

How does Vor Biopharma compare to Tango Therapeutics?

Summary

How does Vor Biopharma compare to Relay Therapeutics?

Summary

How does Vor Biopharma compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. DNTH, EWTX, TNGX, RLAY, and ABCL

How does Vor Biopharma compare to Dianthus Therapeutics?

Does the media refer more to VOR or DNTH?

Is VOR or DNTH more profitable?

Which has better valuation & earnings, VOR or DNTH?

Do analysts recommend VOR or DNTH?

Which has more risk and volatility, VOR or DNTH?

Do insiders & institutionals hold more shares of VOR or DNTH?

Summary

How does Vor Biopharma compare to Edgewise Therapeutics?

Do analysts recommend EWTX or VOR?

Does the media prefer EWTX or VOR?

Is EWTX or VOR more profitable?

Do insiders and institutionals hold more shares of EWTX or VOR?

Which has stronger earnings and valuation, EWTX or VOR?

Which has more risk & volatility, EWTX or VOR?

Summary

How does Vor Biopharma compare to Tango Therapeutics?

Which has more risk & volatility, VOR or TNGX?

Do analysts rate VOR or TNGX?

Does the media favor VOR or TNGX?

Which has preferable earnings & valuation, VOR or TNGX?

Do insiders & institutionals have more ownership in VOR or TNGX?

Is VOR or TNGX more profitable?

Summary

How does Vor Biopharma compare to Relay Therapeutics?

Do insiders and institutionals have more ownership in VOR or RLAY?

Does the media refer more to VOR or RLAY?

Which has more volatility and risk, VOR or RLAY?

Do analysts prefer VOR or RLAY?

Is VOR or RLAY more profitable?

Which has stronger valuation and earnings, VOR or RLAY?

Summary

How does Vor Biopharma compare to AbCellera Biologics?

Which has preferable valuation & earnings, VOR or ABCL?

Do analysts prefer VOR or ABCL?

Does the media favor VOR or ABCL?

Which has more risk & volatility, VOR or ABCL?

Is VOR or ABCL more profitable?

Do institutionals & insiders hold more shares of VOR or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools